Background. We conducted a case-control study to evaluate whether patients with severe gastric atrophy (indicated by serum pepsinogen concentration) have a high risk of gastric cancer. Methods. At the time of diagnosis of gastric cancer, sera from 301 patients (cases) and 602 sex-and age-matched cancer-free individuals (controls) were tested for the presence of antiHelicobacter pylori IgG antibody (HM-CAP enzyme-linked immunoassay [ELISA] kit; Kyowa Medix, Tokyo, Japan) and serum pepsinogen (PG) levels (PG I and II Riabead Kits; Dainabot, Tokyo, Japan). We defined positivity for pepsinogen a pepsinogen I concentration of less than 70 ng/mL and a PG I/II ratio of less than 3.0. We categorized the subjects according to serum pepsinogen levels and anti-Helicobacter pylori IgG antibody, creating four categories. Results. Of the 301 cancer cases, 177 had positive serum pepsinogen levels, and 172 were positive for anti-Helicobacter pylori IgG antibody. The category in which subjects had positive serum pepsinogen levels and were negative for antiHelicobacter pylori IgG antibody had the highest proportion (76.9%) of individuals with gastric cancer and the highest odds ratio (4.20) of the four categories. The odds ratios were 2.55 (95% confidence interval; 1.92-3.88) for positive serum pepsinogen levels and 0.93 (95% confidence interval; 0.63-1.27) for positive anti-Helicobacter pylori IgG antibody. Conclusion. These results suggest that patients with positive serum pepsinogen levels who are negative for IgG antibody to Helicobacter pylori, constitute a high-risk group for gastric cancer. Helicobacter pylori infection is associated with the development of gastric cancer by providing a suitable environment i.e., severe gastric atrophy, for carcinogenesis of the gastric mucosa.
Introduction
Gastric cancer is one of the leading causes of mortality in Japan and many risk factors have been implicated [1] . Many case-control studies have found an increased cumulative risk of gastric cancer and precancerous conditions in individuals with Helicobacter pylori antibodies [2] [3] [4] . Based on this epidemiologic evidence, the World Health Organization (WHO) International Agency for Research on Cancer concluded: There is sufficient evidence that H. pylori has a causal role in the chain of events leading to gastric cancer [5] .
However, there are several problems with regard to the association between H. pylori infection and gastric cancer. First, there is no infected model of H. pylori with subsequent gastric cancer, and the mechanism of gastric cancer growth has not been made clear at the gene level. Secondly, atrophy and metaplasia are implicated in the pathogenesis of gastric cancer of the intestinal type, whereas gastric cancer of the diffuse type does not clearly coexist with atrophy and metaplasia.
Several reports have shown that the extent of atrophy in gastric mucosa without H. pylori infection does not increase with age [6] [7] [8] [9] [10] [11] [12] . Mucosa with severe atrophic gastritis is, however, associated with an increased risk of gastric cancer [6] [7] [8] [9] [13] [14] [15] [16] [17] [18] . Therefore, it is now suggested that H. pylori infection, through the development of atrophic gastritis, is an indirect cause of gastric cancer.
We conducted a case-control study to evaluate the effect of H. pylori infection on the development of gastric cancer. We also investigated the risk of gastric cancer in patients with severe atrophic gastritis.
Department of Medicine, Yamanashi Medical University Hospital, in Yamanashi, Japan. Patients with multiple gastric cancers (n ϭ 65) were excluded from our analysis, because the evaluation of tumor characteristics becomes complicated. Twenty-five patients who had previously undergone partial gastrectomy were also excluded, as atrophy of the gastric mucosa was marked in the gastric remnant, and its extent depended on the interval after surgery. Blood samples of 130 patients had not been stored at the time of diagnosis. Accordingly, 301 patients (213 men, 88 women, mean age at 64 years) were selected as case patients. Blood samples were drawn at the time of diagnosis in the 301 cases, and the separated sera were individually stored at less than Ϫ80°C until tested. Control subjects (n ϭ 602) were selected from among cancer-free, non-peptic ulcer, and non-gastric remnant patients determined by gastroscopy during health check-ups carried out at Yamanashi Koseiren Medical Center. The control subjects were matched to the cases according to sex and age (within 3 years). The blood samples for routine laboratory tests at the health check-up were drawn after the patients had fasted, and aliquots of the separated sera were individually stored at less than Ϫ80°C until tested. We obtained 301 matched sets with one case and two controls. The study was accepted by the Ethics Committee of the Institution, and all participating patients gave their informed consent.
Serological test
H. pylori infection was determined by testing for the presence of anti-H. pylori IgG antibody, using an HM-CAP enzyme-linked immunoassay (ELISA) kit (Kyowa Medix, Tokyo, Japan), and subjects with a titer higher than 2.2 were considered positive for H. pylori infection. Serum pepsinogen (PG) concentrations were measured using pepsinogen I and II Riabead Kits (Dainabot, Tokyo, Japan), a modified radioimmunoassay method described previously [15] . We regarded as PG-positive those subjects with a PG I concentration of less than 70 ng/ml and a pepsinogen I : II ratio (I/II ratio) of less than 3.0 [16] .
Methods
We categorized the subjects according to their serum PG concentration and anti-H. pylori IgG antibody titer (Table 1) , creating four categories. Category A, positive for serum PG concentration and anti-H. pylori IgG antibody; category B, negative for serum PG concentration and anti-H. pylori IgG antibody; category C, positive for serum PG concentration and negative for anti-H. pylori IgG antibody; and category D, negative for serum PG concentration and positive for anti-H. 2 test was used to compare the prevalence of H. pylori infection and positive serum PG in cases and controls. The subjects mean ages in the categories were compared using the Mann-Whitney U-test. A matched case and control study design was used to identify cases and controls for the serum test. Odds ratios (OR), which approximate the relative risk, with 95% confidence intervals (CI) were determined using the Mantel-Haenzel method. Probability values less than 0.05 were considered significant.
Results

Gastric cancer cases
The 301 gastric cancer cases consisted of 213 men and 88 women, with a mean age of 64.0 years. We categorized the cases into two each classes by age, sex, and depth of invasion the (the characteristics of these subgroup analyses are shown in Table 2 ). There was no significant difference in mean age between the men and the women. We classified depth of invasion as "early" or "advanced" stage. Early stage gastric carcinoma was defined as tumor localized at the deepest level within the submucosa, and advanced stage gastric carcinoma as tumor invading the muscularis propria or beyond. We did not find any difference in mean age between patients with early stage gastric carcinoma and those with advanced stage. There were no significant differences in mean serum PG I concentrations and PG I/II ratios between either men and women, patients with early or advanced stage gastric carcinoma or patients aged less than 59 years and those aged more than 60 years (MannWhitney U-test). We also found no differences in the percentages of patients who were PG-positive between men and women, between early stage and advanced stage gastric carcinoma, or between those aged less than 59 years and those aged more than 60 years (chi-square test). Men had a significantly higher positivity rate for H. pylori infection than women (chi-square test). There were no significant differences in H. pylori infection positivity rates between patients with early stage and advanced stage gastric carcinoma, or between those aged less than 59 years and those aged more than 60 years (chi-square test).
Comparison of cases and controls
The relevant characteristics of the 301 cases and 602 controls are shown in Table 3 . We did not find any differences in mean serum PG I and PG II concentration between cases and controls. Cases had significantly lower PG I/II ratios than controls (P Ͻ 0.001, MannWhitney U-test) and significantly higher rates for positive serum PG concentration than controls (P Ͻ 0.001, chi-square test). There was no significant difference in the percentages positive for H. pylori infection between cases (57.1%) and controls (61.6%) (chi-square test). Table 4 shows the association between serum PG and H. pylori antibody in the cases. The association between serum PG and H. pylori antibody in controls is shown in Table 5 . The mean ages of controls increased in the order category B to D to A to C. It is assumed that this order was strongly related to the development of atrophy in gastric mucosa. Table 6 summarizes the association between serum PG and H. pylori antibody in cases and controls. Of the four categories, category C had the highest percentage of gastric cancer cases (64.3%). The proportion of gastric cancer cases increased in the order of B to D to A to C. This order was also related to increasing atrophy in the gastric mucosa. Thus, category C, with low serum PG concentration and negative for H. pylori IgG antibody, is a high risk group for gastric cancer. The odds ratios for the categories are also shown in Table 6 . Category C had the highest odds ratio (4.20; 95% CI, 2.66-6.04) of the four categories.
Association between serum PG and H. pylori antibody
cantly associated with gastric cancer. The results of subgroup analyses are also shown in Table 7 . Significant associations between positive serum PG concentration and cancer were observed in all subgroups.
Discussion
In recent years, there have been many studies of the relationship between H. pylori infection and gastric cancer [2] [3] [4] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The major findings of these 21 studies (including this study) are compared in Table 8 .
Nine of the above studies reported a significant association between H. pylori infection and gastric cancer (OR, range, 2.6-13.3). In 19 of the studies, H. pylori infection was determined by serum IgG antibody to H. pylori. Ten of the studies were nested case-control studies, and the other 11 were cross-sectional case-control studies. Forman et al. [36] reported a significant trend towards an increased OR with increasing time between blood sample collection and cancer diagnosis, by multivariate analysis. The nested case-control studies seemed to show high ORs because the blood samples were collected long before the cancer diagnosis.
Five of the ten nested case-control studies showed a positive association between H. pylori infection and gastric cancer. Of these five studies, three were conducted in countries with a low prevalence of H. pylori Positive PG, Subjects with serum PG I concentration less than 70 ng/ml and PG I/II ratio less than 3.0; negative PG, subjects with serum PG I concentration more than 70 ng/ml or PG I/II ratio more than 3.0; positive for H. pylori antibody, subjects with titer more than 2.2; negative for H. pylori antibody, subjects with a titer less than 2.1 
Association between H. pylori infection and cancer
The matched odds ratio of H. pylori infection and gastric cancer was 0.93 (95% CI, 0.63-1.21; Table 7 ). No significant association between H. pylori infection and gastric cancer was observed. The results of subgroup analyses by age, sex, and depth of tumor invasion are also shown in Table 7 . The odds ratio in the group less than 59 years was high (1.53; 95% CI, 0.91-2.59).
Association between positive serum PG concentration and cancer
The matched odds ratios for positive serum PG concentration and gastric cancer was 2.55 (95% CI, 1.92-3.38; Table 7 ). Positive serum PG concentration was signifi-these four studies were conducted in a younger population (aged less than 50 years). Case-control studies in young populations have high ORs as the seropositivity rate of H. pylori infection in the matched controls is relatively low. The study of Barreto and colleagues [22] had a low seropositivity rate of H. pylori infection in controls, and that of Asaka and colleagues [21] had a high seropositivity rate of H. pylori infection in cases. Two factors that influence the OR are the prevalence rate of the risk factor in the population, and the interval between serum collection and diagnosis. [37] . The study of Nomura et al. [3] reported a high seropositivity rate of H. pylori infection in cases, and the study of Hansson et al. [25] reported a low seropositivity rate of H. pylori infection in their matched controls. The remaining five nested case-control studies were conducted in countries with a high prevalence of H. pylori infection (Japan, Taiwan, China, and Finland) [37] . Four of the 11 cross-sectional case-control studies reported a positive association between H. pylori infection and gastric cancer. Two of Our results do not support the hypothesis that H. pylori infection plays a role in gastric cancer carcinogenesis, as our study showed a low prevalence of H. pylori infection in the gastric cancer cases. Most cancer cases with seronegativity for H. pylori infection belonged to category C (positive for serum PG concentration and negative for H. pylori infection). Category C had the highest percentage of gastric cancer cases of all categories. Most of the subjects in category C had extensive mucosal atrophy (indicated by low PG I and low PG I/II ratio), and this may cause spontaneous loss of H. pylori from the stomach. Our results suggested the following theory. First, H. pylori infection caused anti-H. pylori IgG antibody seropositivity, in result subjects in category B changed to those in category D. Next, chronic gastritis due to H. pylori infection, caused extensive mucosal atrophy, in result subjects in category D changed to those in category A. Finally, the extensive mucosal atrophy led to the spontaneous loss of H. pylori from the stomach, in result most of subjects in category A changed to those in category C. Indeed, the gastric mucosa in category C subjects showed the greatest extent of mucosal atrophy, due to H. pylori infection, and subjects in this category had the highest risk of gastric cancer among our four categories. Previous studies have also suggested that loss of H. pylori colonization and subsequent loss of seropositivity may occur frequently in conditions such as severe atrophic gastritis and intestinal metaplasia [24, 32, 38] . Thus, false-negative results for H. pylori infection may have been frequent in gastric cancer cases in blood samples taken at the time of cancer diagnosis, because loss of seropositivity may have occurred in the gastric cancer patients with severe gastric atrophy.
Serum PG concentrations (low PG I and low PG I/II ratio) are considered to be a reliable marker of chronic atrophic gastritis [18, [39] [40] [41] , and are useful for the screening of gastric cancer [6] [7] [8] [9] [13] [14] [15] [16] [17] [18] . The severity of atrophic gastritis is well correlated with serum PG I concentration and with PG I/II ratio [39, 42] . Therefore, atrophic gastritis was associated with a significantly increased risk of gastric cancer (OR, 6.59; 95% CI, 3.45-12.57) in our study, as we used the serum PG concentration as a marker of extensive mucosal atrophy.
In conclusion, our results suggest that H. pylori infection leads to severe atrophic gastritis and intestinal metaplasia in the gastric mucosa, with gastric cancer eventually occurring in this environment. Therefore, it appears that H. pylori infection is one of the indirect causes of gastric cancer, via the development of atrophic gastritis. Individuals who have severe atrophy and intestinal metaplasia in the gastric mucosa have the highest risk of gastric cancer. False-negative assessments of H. pylori infection may be frequent in this high-risk group.
H. pylori seems not to act as an initiator in the development of gastric cancer, but as a promoter in the progression from normal mucosa to severe atrophy. However, it seems that H. pylori infection alone is neither necessary nor sufficient for the development of gastric cancer. Dietary factors, such as excessive salt intake and diets low in fresh fruits and vegetables; smoking; and genetic factors may still play important roles in gastric cancer carcinogenesis [30, [43] [44] [45] [46] [47] . The role of H. pylori infection in the complex multifactorical carcinogenesis of gastric cancer needs to be explored further in the light of the multistep theory of gastric carcinogenesis.
